64.97
+0.01(+0.02%)
Currency In USD
Address
188 East Blaine Street
Seattle, WA 98102
United States of America
Phone
206 788 4545
Sector
Healthcare
Industry
Biotechnology
Employees
142
First IPO Date
June 17, 2015
| Name | Title | Pay | Year Born |
| Dr. Mitchell H. Gold M.D. | Executive Chairman & Chief Executive Officer | 1.02M | 1968 |
| Mr. Paul Rickey | Senior Vice President, Chief Financial Officer, Treasurer & Secretary | 691,100 | 1979 |
| Dr. Stanford Peng M.D., Ph.D. | President and Head of Research & Development | 940,100 | 1971 |
| Dr. Remy Durand Ph.D. | Chief Business Officer | 0 | 1986 |
| Mr. Ulrich Martin Fuhs | Vice President of Finance & Chief Accounting Officer | 0 | 1968 |
| Ms. M. Christina Yi | Chief Technology Officer | 0 | 1976 |
| Ms. Michelle Greenblatt | Director of Investor Relations & Corporate Communications | 0 | N/A |
| Dr. Andrew Seth Sandler M.D. | Chief Medical Officer | 0 | 1965 |
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.